Nebulized Hypertonic Saline for Inpatient Use in COPD

• Status: Completed
• Trial end date: 2017-01-30
• Target enrollment: 0
• Participant gender: All

Summary

A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OhioHealth

Criteria

Inclusion Criteria:

• Patients at least 18 years of age

• Admitted to Doctors Hospital with a clinical diagnosis of COPD

• Documented obstruction on spirometry from prior records available at the time of the study.

Exclusion Criteria:

• Patients younger than 18 years of age

• Spirometry data not available

• History of smoking less than twenty pack-years

• Possibility of other primary cause of the patient's change in dyspnea or cough (e.g. pneumonia, congestive heart failure with pulmonary edema, myocardial infarction)

• Patient is found to have a different primary cause after initial enrollment

• Non-English speaking subjects